Growth hormone and nutritional support: adverse metabolic effects.
The use of growth hormone in clinical nutritional support has received considerable attention over the past decade. The most encouraging results have been improved nitrogen retention and protein synthesis in the presence of hypocaloric nutritional support. Adverse effects, however, can limit the clinical usefulness of this technology. In the following case study, an obese 71-year-old man with a history of chronic obstructive pulmonary disease remained ventilator dependent 2 months following anterior cervical fusion and had severe depletion of visceral proteins despite nitrogen equilibrium. He was treated with 10 mg of recombinant human growth hormone (Genentech) subcutaneously every other day while also receiving nutritional support. We hypothesized that growth hormone administration could promote both protein synthesis and the development of muscle mass, particularly in the respiratory muscles, without increasing nutrient intake and, therefore, without increasing CO2 production. The patient, however, developed two potentially life-threatening adverse effects: hyperglycemia and fluid retention. The severity of these adverse effects led to discontinuation of this mode of therapy.
Lehmann
S
S
Cerra
F B
FB
D000368:Aged; D004750:Enteral Nutrition; D013006:Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D007279:Injections, Subcutaneous; D008297:Male; D015596:Nutrition Assessment; D011502:Protein-Energy Malnutrition / Q000188:drug therapy*; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced*
D013006:Growth Hormone